ARCHIVES

Steven Woolf: Why CMS Should Not Cover LDCT

This article is from The Cancer Letter archive.

Vol. 40 No. 19 | May 9, 2014

Download PDF Visit The Full Archive

Related Articles

Genitope Therapy In Phase III Trials For Low-Grade B-Cell Non-Hodgkin’s.

October 26, 2001

Cephalon To Plead Guilty, Pay $425M For Off-Label Marketing.

October 3, 2008

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

August 31, 2012

Funding opportunities listed.

February 6, 2004

HHS Approves States Plans For Breast, Cervical Cancer Treatment For Uninsured.

April 6, 2001

Clinical Oncology Program Overview Updates Ongoing Trials

December 8, 1989